Navigation Links
Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World
Date:5/6/2010

LEIDEN, The Netherlands, May 6, 2010 /PRNewswire-FirstCall/ -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced the award from UNICEF of an additional $110 million to supply its paediatric vaccine Quinvaxem(R) to the developing world. Paediatric vaccination plays an important role in contributing to achieving the Millennium Development Goals set by the United Nations, in particular the target of reducing under-five mortality rate by two-thirds between 1990 and 2015. "We are proud to be able to deliver significant amount of additional vaccine orders at short notice," said Ronald Brus, Crucell's Chief Executive Officer. "The capacity and reliability of Crucell's manufacturing and logistical systems allows us to deliver high quality and safe vaccines to protect young children from life threatening diseases in the world's developing countries. As a responsible and reliable partner, we thus contribute to the success of the Global Alliance for Vaccines and Immunisation (GAVI Alliance) in accelerating access to these vaccines across the globe."

From 2006-2009 as part of the Extended Program for Immunization, over 130 million doses of Quinvaxem(R) have been delivered to more than 50 countries. Crucell has been increasing its production capacity over the last few years in order to meet the growing demand for paediatric vaccines from the developing world.

Quinvaxem(R) is the only fully liquid pentavalent DTwP-HepB-Hib vaccine that is free from the preservative thiomersal. It is an optimal solution for protection against five potentially deadly childhood diseases: diphtheria, tetanus, pertuss
'/>"/>

SOURCE Crucell N.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
2. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
3. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
4. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... DIEGO, Jan. 3, 2012  Amylin Pharmaceuticals, Inc. (Nasdaq: ... Morgan Healthcare Conference in San Francisco on Monday, January 9, ... Daniel M. Bradbury, president and chief executive officer of ... presentation and break-out session will be webcast through the "Investors" ...
... Renowned biochemist Michael A. Marletta, PhD, assumed the post ... January 1, succeeding Richard A. Lerner, MD, who led ... (Photo:  http://photos.prnewswire.com/prnh/20120102/DC28698 ) "I,m excited ... knowledge in the biosciences and applying that knowledge to ...
... BioNeutral Group, Inc. (OTCBB: BONU), a specialty life ... received $400,000 in connection with the Preferred Stock ... ("Vinfluence"), New South Wales, Australia.  Pursuant to the ... initial closing and a second funding of $200,000, ...
Cached Biology Technology:Michael A. Marletta Takes Office as New President of Scripps Research Institute 2BioNeutral Group Receives $400,000 in Equity Financing 2BioNeutral Group Receives $400,000 in Equity Financing 3
(Date:4/23/2014)... who have had a stroke, often suffer motor deficits ... study conducted in Taiwan, that will be published in ... is currently freely available on-line as an unedited early ... one group of stroke victims had their own peripheral ... and a similar group did not, those who received ...
(Date:4/23/2014)... the energy landscape in the U.S., but in ... the energy industry, residents and agricultural interests over ... degraded water quality is a potential risk unless ... in the ACS journal Environmental Science & ... point out that a major criticism of extracting ...
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... as calcified, inert structures, but researchers at Columbia University ... important novel function of the skeleton. Theyve shown for ... organ that helps control our sugar metabolism and weight ... development of type 2 diabetes. The research, ...
... passed on from mother to child is decided very early ... ovary. In a cell division process that is unique to ... egg before it is fertilised. Using a powerful microscope, researchers ... how the molecular machinery functions that is responsible for chromosome ...
... Haven, Conn. It is not just whats in your genes, ... between species at least in yeast according to a ... Weve known for a while that the protein coding genes of ... author Michael Snyder , the Cullman Professor of Molecular ...
Cached Biology News:Research shows skeleton to be endocrine organ 2A unique arrangement for egg cell division 2Evolution is driven by gene regulation 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... was first identified as the cellular homolog of ... and Jun D have been shown to be ... which are involved in dimerization and DNA binding, ... transcriptional activation, diverge. Antigen: ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
... (IC) Fixation Buffer, used in conjunction ... 00-8333), can be used to fix ... intracellular staining of cytokines and other ... have been specially formulated for reducing ...
Biology Products: